Gone But Not Forgotten The Case for Drug-Eluting Stents in Percutaneous Revascularization of the Chronic Coronary Total Occlusion⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. by Tcheng, James E. & Zidar, David A.
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one But Not Forgotten
he Case for Drug-Eluting Stents in
ercutaneous Revascularization of the
hronic Coronary Total Occlusion*
ames E. Tcheng, MD, David A. Zidar, MD, PHD
urham, North Carolina
he granting of regulatory approval for the treatment of
oronary artery disease with drug-eluting stents has proven
o be a hallmark event in interventional cardiology. Given
he dramatic efficacy of these devices in reducing restenosis,
he interventional community has rapidly extended the
pplication of drug-eluting stents beyond the “approved,”
ut relatively straightforward, nonocclusive lesion types
tudied in pivotal registration trials (1,2) to “off-label”
ndications including the chronic total occlusion. To date,
ew studies have addressed the efficacy and safety of drug-
luting stent implantation in these extended indications.
he study by De Felice et al. (3), in this issue of JACC:
ardiovascular Interventions, helps fill a critical gap of our
edical knowledgebase regarding drug-eluting stents in
omplex coronary lesion subsets.
See page 1260
Given the physical and physiologic properties of drug-
luting stents, coupled with the extensive body of evidence
emonstrating reductions in angiographic restenosis and
linical target lesion and target vessel revascularization, it
hould come as no surprise that the primary finding of the
tudy is also a reduction in target lesion revascularization
8% vs. 21%, p  0.004). Even given the limitations of the
equential cohort, nonrandomized registry design, this is
ndeed good news—especially the 10% rate of (clinically
riven) repeat target lesion interventions. Previous prospec-
ive randomized trials of (early generation) bare-metal stents
ersus balloon angioplasty, including the SICCO (Stenting
n Chronic Coronary Occlusion), GISSOC (Gruppo Ital-
ano di Studio sullo Stent nelle Occlusioni Coronariche),
OSCA (Total Occlusion Study of Canada), and PRISON
Primary Stenting of Totally Occluded Native Coronary
rteries) trials (4–8) (Table 1), demonstrated relatively
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-i
ions or the American College of Cardiology.
From Duke University Medical Center, Durham, North Carolina.nacceptable rates of target lesion revascularization with
are-metal stent implantation. In these studies, whereas
are-metal stent implantation reduced restenosis compared
ith balloon percutaneous coronary intervention, the high
ate loss index of stent implantation resulted in absolute
ates of angiographic restenosis of 22% to 55%. Further-
ore, the problem of reocclusion (not just restenosis) did
ot appear to be solved by bare-metal stent implantation,
ith 8% to 16% rates of occlusion observed in these trials.
hereas the target lesion revascularization end point used
n the current study is obviously not angiographic restenosis,
nd the design did not mandate angiographic follow-up, the
linically relevant reduction in target lesion revascularization
onetheless undoubtedly reflects a proportionate reduction
n true vascular restenosis in this lesion subset.
Even given the positive finding of a reduction in reste-
osis to what most would consider an acceptable level, the
dvantages of drug-eluting stent implantation, unfortu-
ately, do not appear to extend much beyond that singular
nding. Interestingly, this echoes the clinical end point
ndings of the bare-metal stent versus balloon angioplasty
rials—that there may be little clinical benefit of stent
mplantation in chronic coronary total occlusion beyond
educing restenosis and (presumably) improving symptom-
tology. For example, in the TOSCA trial, there was no
tatistically significant difference in 1-year mortality (0.5%
n the balloon angioplasty cohort vs. 1.5% in the stent
ohort, p  NS), whereas rates of protocol-defined myo-
ardial infarction at 1 year were actually higher in the stent
roup (3.8% vs. 12.4%, p  0.012). It is this propensity for
elayed events that was hinted at in the contrasting findings
f the 1- versus 3-year reports from the RESEARCH
Rapamycin-Eluting Stent Evaluated at Rotterdam Cardi-
logy Hospital) study as reported by Hoye et al. (9) and
arcia-Garcia et al. (10), respectively. Between the 1-year
nd 3-year time points in the RESEARCH study, there was
loss of the advantage of drug-eluting stent implantation
ith respect to target lesion revascularization and major
dverse cardiac events. Fortunately, this reversal of fortune
as not seen in the current study, with no differences
bserved in either the 3-year overall major adverse cardiac
vent rates or the mortality or myocardial infarction com-
onents. Even with that, the time line for the 3 cases of
tent thrombosis in the bare-metal stent patients (between 1
nd 8 months) versus the 4 cases of stent thrombosis in the
rug-eluting stent group (all occurring between 22 and 33
onths) bears mentioning. It thus remains an overall
imitation that lowered rates of restenosis have generally not
ranslated into further decrements in myocardial infarction
r mortality, whether in simple or complex clinical or
natomic subsets.
These arguments then bring into question the general
fficacy of percutaneous coronary intervention of the chron-
cally occluded coronary. Rather than appearing nihilistic,
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1267e instead hope that there remain additional clinical bene-
ts that are simply undiscovered because of the limitations
f existing study designs. In this vein, we believe the overall
vidence accrued to date argues for use of drug-eluting
tents in this anatomic subset. The key findings of the
rospective, randomized PRISON II trial strongly contrib-
te to this perspective. In PRISON II, 200 patients were
andomized to the Cypher sirolimus-eluting stent (Cordis
orporation, Miami, Florida) versus the BxVelocity bare-
etal stent (Cordis Corporation). The primary end point,
inary restenosis at 1 year, was lower with the sirolimus
rug-eluting stent (7% vs. 36%, p  0.0001) (11). Impor-
antly, the 3-year follow-up of PRISON II shows continued
ngiographic and overall clinical benefit in the sirolimus-
luting stent group (12).
So what else is needed to complete the picture? To the
redit of De Felice et al. (3), a fairly rigorous definition of
he eligible patient population was applied: documented
otal coronary occlusion of at least 3 months’ duration
oupled with demonstrable ischemia or viability. It is
recisely this group (and not patients just with an angio-
raphically documented total coronary occlusion) that de-
erves continued study. Furthermore, because the advantage
f percutaneous coronary intervention may primarily be in
he relief of symptoms, the constellation of “soft” end points
eflecting symptomatology and other relevant elements
hould not be ignored; systematic inquiry regarding second-
ry end points (for example, angina status, heart failure
ncidence, rehospitalization rates, and medication usage) is
eeded. One plausible explanation for the lack of durability
een by Garcı´a-Garcı´a et al. (10) and its variance with this
urrent study and PRISON II is that a greater appreciation
ow exists for extended antiplatelet therapy. The drug-
luting stent group may have been treated with a greater
uration of dual antiplatelet therapy, which could have
verestimated the impact of stent type on outcomes. Future
Table 1. Quantitative Coronary Analysis of Randomized Trials of Balloon An
Balloon Angioplasty
Trial SICCO GISSOC TOSCA
Baseline MLD 0 0 0
Initial MLD, mm 2.13 1.91 1.96
Follow-up MLD, mm 1.11 0.85 1.23
Late loss, mm 1.02 1.06 0.73
Late loss index 0.48 0.55 0.37
Angiographic restenosis, % 74 68 70
Reocclusion, % 26 34 20
Angiographic follow-up in these trials varied from 88% to 96%.
MLDminimal luminal diameter; SICCO Stenting in Chronic Coronary Occlusion trial; GISSOC
Totally Occluded Native Coronary Arteries trial; TOSCA Total Occlusion Study of Canada trial.tudies will thus need to pay strict attention to the emergingmportance of antiplatelet therapy in modulating long-term
utcomes.
The obvious conclusion is that a large, parallel-group,
rospective study is still needed. In the meantime, the
elcome contributions of De Felice et al. (3) add to the
rowing body of evidence arguing for the use of drug-
luting stents in this off-label population.
eprint requests and correspondence: Dr. James E. Tcheng,
uke University Medical Center, 403 Hock Plaza, 2424 Erwin
oad, Durham, North Carolina 27705. E-mail: tchen001@mc.
uke.edu.
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